Escitalopram Administration, Neuroplastic Effects and Relearning: A Diffusion Tensor Imaging Study in Healthy Individuals

Vanicek T, Reed MB, Unterholzner J, Klöbl M, Godbersen GM, Handschuh PA, Spurny B, Ritter V, Gryglewski G, Kraus C, Winkler D, Lanzenberger R*, Seiger R

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria.

For submission to

bioRxiv

# of words abstract	244
# of words manuscript	2705
# of tables	2

*Correspondence to:

Prof. Rupert Lanzenberger, MD, PD

Email: rupert.lanzenberger@meduniwien.ac.at

Medical University of Vienna, Department of Psychiatry and Psychotherapy, Austria

Abstract

Background Neuroplastic processes are influenced by selective serotonergic reuptake inhibitors, while learning in conjunction with the administration of serotonergic agents alters white matter microstructure in humans. The goal of this double-blind, placebo-controlled imaging study was to investigate the influence of escitalopram on white matter plasticity during (re)learning.

Methods Seventy-one healthy individuals (age = 25.6 ± 5.0 , 43 females) underwent 3 diffusion magnetic resonance imaging sessions: at baseline, after 3-weeks of associative learning (emotional/non-emotional content) and after relearning shuffled associations for an additional 3 weeks. During the relearning phase, subjects received daily escitalopram 10 mg or placebo orally. Statistical analysis was performed with statistical parametric mapping (SPM) and using sandwich estimator.

Results A three-way and two-way rmANOVA was conducted to analyze the effects of escitalopram on AD, FA, MD and RD during the learning and relearning period. We found no significant three-way or two-way interactions for each DTI metrics ($p_{FDR} > 0.05$), thus neither after 3 nor after 6 weeks we found significant changes in white matter microstructure.

Conclusion We examined neither an effect of escitalopram nor learning (or relearning) interventions on different DTI metrics. The duration and intensity of study interventions (i.e. administration of escitalopram and learning as the relearning task) might have been chosen insufficiently to induce detectable alterations. Previous studies examining the effects of SSRIs on white matter tracts in humans are underrepresented, but do mainly yield towards non-significant findings. The results implicate that escitalopram does not impact white matter microstructures in healthy subjects.

Introduction

Antidepressants and in particular selective serotonin reuptake inhibitors (SSRIs) present a well-established and frequently applied treatment option for patients with mood and anxiety disorders (Bauer et al., 2013). Therapeutic agents modulating monoaminergic neurotransmission have been found to restore well-being with regard to different symptom complexes including depression, anxiety or obsessions and compulsions. According to the monoamine deficiency theory (Delgado, 2000), treatment-induced changes in mood following SSRI administration are physiologically related to a blockage of the serotonin transporter and subsequent up-regulated serotonin levels in the synaptic cleft that stimulates auto- and hetero-receptors located at serotonergic neurons and projection areas (Spies et al., 2015).

Throughout the last decade the influence of SSRIs on brain structure has been primarily investigated by exploiting T1-weighted magnetic resonance imaging (MRI). Most structural imaging investigations were conducted in patients with receiving SSRIs as a study and treatment intervention and results are partly heterogeneous. (Kraus et al., 2017). SSRI studies in healthy subjects and patients using MRI predominantly examine drug-induced changes in neuronal activation and functional connectivity (Dichter et al., 2015). Pharmacological studies on SSRI in healthy individuals and structural MRI are astonishingly scarce (Kraus et al., 2014; Shively et al., 2017). In longitudinal studies, cognitive or physical training and learning as well as administered SSRIs were found to impact brain morphology (Kristensen et al., 2018; Knorr et al., 2019). Also, SSRI intervention studies demonstrated treatment-associated changes in white matter integrity in different clinical samples with diverse methodological approaches (Yoo et al., 2007; Fan et al., 2012; Seiger et al., 2021).

Although SSRIs have been comprehensively studied on a cellular level in animal models and humans *in-vivo*, the mechanisms underlying their therapeutic potential in neuropsychiatric disorders are not well understood. Due to the partly insufficient and yet unexplained remission and response rates of approximately 40% to 60% following antidepressant treatment, respectively (Trivedi et al., 2006), the

notion that SSRIs do not directly improve mood and thus cause depression to resolve, but instead enable susceptibility to change irrespective of direction has been increasingly studied and propagated (Chiarotti et al., 2017). SSRIs and fast-acting antidepressants as ketamine have been demonstrated to facilitate neuroplasticity (Alboni et al., 2017; Casarotto et al., 2021). According to this hypothesis, the brain is then suggested to be more prone to the quality and amplitude, implicating that the outcome of an SSRI treatment is dependent on encouraging or stressful influences one experiences (Branchi and Giuliani, 2021).

On the basis of imaging studies, convincing evidence points towards a relation between white matter integrity, plasticity and intellectual development of the central nervous system during child- and adulthood (Wang and Young, 2014; Bells et al., 2019). Apart from age-related changes of white matter throughout lifespan, which peak in the third and decline from the fifth decade onward (Dvorak et al., 2021), longitudinal neuroimaging studies revealed an effect of experience on white matter that can be traced with diffusion weighted imaging (Zatorre et al., 2012). Investigations in animals and humans show that white matter changes dynamically and dependent of the standardized study-experience *in vivo* following training (Keller and Just, 2009; Blumenfeld-Katzir et al., 2011). For instance, motor exercise learning as juggling increased fractional anisotropy (FA) in the right posterior intraparietal sulcus, an area associated with hand-eye co-ordination, and prevailed for at least 4 weeks following training (Scholz et al., 2009). The majority of white matter studies examined an increase in FA, and positive effects working memory on FA in parietal tracts (Takeuchi et al., 2010). In addition, perceptual learning such as texture discrimination learning or Braille reading training altered white matter, reflected in elevated FA (Yotsumoto et al., 2014; Debowska et al., 2016).

Within the last decade, diffusion tensor imaging (DTI) emerged as a reliable and frequently applied imaging approach to non-invasively investigate white matter microstructure. Although water diffusivity metrics are too coarse to comprehensively relate those findings to specific cellular mechanisms that are involved in white matter neuroplasticity, multimodal investigations in rodents have identified a significant overlap of molecular and cellular changes and white matter plasticity

measured by diffusion MRI (Sampaio-Baptista et al., 2020). Several diffusion metrics have been found useful to describe differences between groups or over time (Smith et al., 2006). Among these metrics, FA provides information on the directionality of the diffusion process, hence, reflecting the grade of anisotropy and myelination. Axons allow water molecules to diffuse quickly along the direction of organization (axial diffusivity; AD), but constraining radial diffusivity (RD) meant to perpendicular travel along the direct axis. Mean diffusivity (MD) estimates the average water diffusion across all directions.

To reveal potential neuroplastic effects that SSRIs have on white matter during relearning, we performed a longitudinal placebo-controlled interventional learning study. Healthy subjects performed an associative learning task either with or without emotional content, where face pairs or pairs of Chinese characters and unrelated German nouns had to be memorized. After 21 days, subjects had to learn shuffled associations (i.e. relearning) within the same group for another 21 days. During the relearning period, subjects received either escitalopram 10 mg/day, or placebo. DTI models were estimated before and after associative learning and relearning periods.

Methods

Subjects and study design

Study participants were randomly assigned to one of four groups prior to study inclusion as follows: SSRI: 17 character-group, 16 faces-group; Placebo: 15 character-group, 23 faces-group. The design has been described in detail in previously published studies (Reed et al., 2021; Spurny et al., 2021). In brief, diffusion MRI scans were carried out before and after an associative learning period of 3 weeks as well as after a subsequent 3-week associative relearning under SSRI/placebo treatment. During the associative relearning period subjects received daily escitalopram 10 mg (Cipralex® Lundbeck A/S, provided by the Pharmaceutical Department of the Medical University of Vienna) orally or placebo. To ensure compliance, venous blood was drawn from the cubital vein to assess citalopram plasma through

levels 1 week and 2 weeks into drug administration and before the third MRI. The therapeutic reference range for escitalopram it is 15-80 ng/mL (Hiemke et al., 2011).

The learning paradigm was divided into 2 groups (with or without emotional valence), where participants had to learn either face pairs or pairs of Chinese characters and unrelated German nouns. During the relearning phase the learning content was shuffled. During each phase, 200 image-pairs per group had to be learned or relearned with a daily subset of 52 image pairs. All faces were derived from the “10k Adult Faces Database” (Bainbridge et al., 2013).

Data acquisition

The diffusion-weighted images (DWI) were acquired with a 3 Tesla Siemens MR scanner (MAGNETOM, Prisma, Siemens Medical, Erlangen, Germany) using a 64-channel head coil. 57 diffusion encoded images, with a b-value of 800 s/mm² along with 13 non-diffusion (b=0) images were recorded (TR=9400 ms, TE=76 ms, slice thickness=1.6 mm, resolution=1.6x1.6 mm, matrix size=128x128x75, flip angle=90°, acquisition time=11:45 min). Subjects were instructed to keep their head as still as possible during the entire scan to minimize movement artifacts. Additionally, their heads were stabilized with foam cushions.

Data processing

Data processing was conducted within the FMRIB software library (FSL, v. 5.0.11) (Smith et al., 2004) with the standard TBSS pipeline (Smith et al., 2006). All data outside of the brain were masked out (Smith, 2002), corrected for movements, geometric distortions and eddy currents as well as for outliers in the form of signal dropout (J. L. R. Andersson et al., 2016; J. L. R. Andersson and Sotiropoulos, 2016). The diffusion tensors were fitted using the dtfit command as well as the rotated b-vectors gained from the prior eddy current correction step. For the TBSS analysis, FA maps were eroded and brought into standard space using FNIRT (J. L. R. Andersson, Jenkinson, M., and Smith, S., 2007a; J. L. R. Andersson, Jenkinson, M., and Smith, S. M., 2007b). The data from each subject was then projected onto the

FMRIB58_FA mean FA image and skeleton. The skeletonized images of all subjects were further used for voxel-wise statistics. In addition, the `tbss_non_FA` command was utilized to generate the skeletonized maps for the remaining parameters, AD, MD and RD.

Statistical analysis

We applied an ANOVA as well as a Pearson's chi-squared to test for similarities or differences between randomized groups. To reveal potential effects of escitalopram and (re)learning content have on both learning as well as relearning on DTI metrics, separate three-way repeated measures analyses of variance (rmANOVAs) for AD, FA, MD and RD were performed. We tested for interaction effects between substance (escitalopram vs placebo) x content (emotional vs. semantic learning and relearning) x time. Interaction effects were dropped in case of non-significance. To correct for different brain sizes and volumes the total intracranial volume was included as a covariate. The significance threshold was set at $p \leq 0.05$ False discovery rate (FDR) was used to correct for all post-hoc comparisons. Statistical analysis was performed using the sandwich estimator (SwE) as implemented in statistical parametric mapping (SPM).

Results

Study population

Hundred and thirty-eight healthy subjects were included, but 54 subjects did not complete both the learning and relearning period (see Flow-diagram, Table 1). Data from 71 healthy subjects (age = 25.6 ± 5.0) measured at three time points in a randomized, double blind, placebo-controlled manner were included in this DTI analysis. The four groups did not significantly differ in terms of age and gender, as shown by the ANOVA: $F(3,67) = 0.025$, $p=0.995$ and the Pearson's chi-squared test: $X^2 = 2.24$, $df = 3$, $p\text{-value} = 0.524$. Detailed demographical results can be found in Table 2.

Analysis of DTI metrics over time

To test if escitalopram (vs. placebo) effects AD, FA, MD and RD during the learning and relearning period and if learning content (emotional vs. semantic) is relevant, a three-way and two-way rmANOVA were conducted first to analyze interaction effects. We observed no significant three-way interactions for each DTI metrics ($p_{FDR} > 0.05$). Further, we also found no interaction between learning as well as relearning and time and no interaction between substance and time.

Discussion

Given preclinical reports on the neuroplastic effects of SSRI and its relevancy for neuropsychiatric disorders, we aimed to investigate the influence of escitalopram on white matter microstructure *in vivo* during relearning. We examined no influence of escitalopram on DTI metrics during the relearning period. Further, neither learning (2nd MRI at day 21) nor relearning (3rd MRI at day 42) lead to significant differences in AD, FA, MD and RD. Here, learning content (emotional or semantic content) also had no influence on white matter.

Work by our group demonstrated immediate changes in diffusivity parameters following intravenous SSRI-administration. In a PET/MRI intervention study, patients with depression and healthy controls received citalopram 8 mg intravenous, which was described to sufficiently occupy the serotonin transporter (Gryglewski et al., 2019). Citalopram led to attenuated MD, AD and RD in the anterior corona radiata, corpus callosum, external capsule and frontal blade in patients and controls, without affecting FA or increasing any DTI metric (Seiger et al., 2021). Also, short and intensive learning has been found to affect white matter microstructure (Hofstetter et al., 2013), suggesting that cellular rearrangement in this compartment occurs rapidly (Sagi et al., 2012).

In comparison to these short-time effects of SSRI, here, we administered escitalopram over a period of 3 weeks and depicted no effects on white matter microstructure. In a DTI study in patients with

obsessive-compulsive disorder, decreased MD and RD in midbrain regions and striatum were observed following 12 weeks of SSRI treatment, while changes in FA were not detected (Fan et al., 2012). These findings link SSRI to diminished FA and AD, indicating a reduction in longitudinal water diffusion. Also, disorder-specific symptoms decreased significantly following 12 weeks of citalopram treatment in patients with obsessive-compulsive disorder in comparison to controls, while FA was higher before treatment initiation and diminished over time in the corpus callosum, internal capsule and adjacent structures to the right caudate. However, the findings were not corrected for multiple comparisons (Yoo et al., 2007). Effects of SSRI on diffusivity parameters in patients with depression were found divergent in two studies. One study found unspecific white matter volume alterations across different areas after 12 to 16 weeks of SSRI-treatment in 17 patients with depression, though, only if significant levels were chosen less conservative (Zeng et al., 2012). In a multicenter study 200 patients with depression were measured 3 times across 8 weeks. Interestingly, Davis et al. found changes at baseline in comparison to control subjects, but no longitudinal white matter changes across the 8-week timespan (Davis et al., 2019). Our study findings appear to reflect these reports, since SSRI interventions have been mainly found to not propagate changes of DTI metrics, in particular when analyses are performed with conservative measures. Then, the timespan of 3 weeks of escitalopram administration was distinctively shorter than in other white matter studies, where certain changes over time were demonstrated. Nevertheless, this duration was found reasonable for SSRIs to promote neuroplastic effects and unfold efficacy in clinical settings (Bauer et al., 2013; Alboni et al., 2017).

For long, human behavior and perception was understood as an effector of neuronal activity, with the synapse as the primary location for cell communication and thus neuroplasticity, while white matter was reduced to a (in-)homogeneous structure serving as a medium for proper transfer of information. Intervention studies led to the conception that the plasticity phenomena not only occurs in grey matter, where environmental stimuli are known to shape synaptic organization (Draganski et al., 2004), but are relevant for the reorganization of white matter likewise (Sampaio-Baptista and Johansen-Berg, 2017). Activity-dependent changes of myelination architecture are found to affect

neuronal networks (Hartline and Colman, 2007; Ford et al., 2015). Non-pharmacological interventions as motor skill learning or cognitive training have been found to be associated with DTI-changes in healthy subjects and patients with mental disorders. These effects were demonstrated to be dependent on time or training load, since interventions with an interval less than 8 weeks did not generate pre-post differences in white matter (Kristensen et al., 2018). Here, we examined no effects of learning or relearning intervention on DTI metrics, indifferent if learning groups with emotional or semantic content were compared or learning groups were pooled together. In the same study sample, metabolic and functional changes have demonstrated after relearning and escitalopram administration. In a task-based fMRI analysis, neuronal activation was found to be decreased in the insula after relearning in subjects that were administered escitalopram (Reed et al., 2021). Further, we found a relationship between escitalopram and relearning when comparing glutamate levels in the hippocampus and thalamus before and after associative relearning (Spurny et al., 2021). These findings underline the effects of escitalopram and learning on various brain measures and we expected learning induced white matter changes. Nevertheless, it is probable that learning intensity and duration were designed to sparse to propagate adaptations in the white matter compartment.

Within the group that received escitalopram during reversal learning, half of the subjects developed citalopram blood levels beneath the therapeutic range. In clinical studies, patients receiving SSRIs have generally not been found to significantly benefit from dose escalation strategies, since response rates are found similar for therapeutic dose and high-dose treatment, but less tolerability and acceptability occurred in treatment with higher doses (Adli et al., 2005; Furukawa et al., 2019). Already very low doses of citalopram, the racemic precursor substance of escitalopram, lead to a serotonin transporter occupancy of 50 %, while 80 % occupancy was depicted at therapeutic citalopram dosing, that is equivalent to the applied dose of escitalopram (i.e. 10 mg daily) in our study (Meyer et al., 2004; Shapiro, 2018). However, antidepressants are found to induce neuronal plasticity in dependence of drug dose in clinical samples (Chiarotti et al., 2017). Taken together, therapeutic doses of escitalopram 10 mg should have sufficiently stimulated serotonergic neurotransmission and prevented from higher

drop-out rates, though mediocre citalopram blood levels across our study individuals could have affected study outcomes.

We aimed to reveal a relationship between SSRI treatment, neuroplastic effects on white matter properties and reversal learning in humans *in vivo*. Results show neither an effect of escitalopram nor learning or relearning interventions on DTI metrics. The duration and intensity of study interventions, i.e. administration of escitalopram and learning as the relearning task, might have been chosen insufficiently to induce detectable effects.

Acknowledgements

We wish to thank the team members as well as the medical students of the Neuroimaging Lab (NIL), headed by Prof. Lanzenberger, the corresponding author. Also, we thank T. Stimpfl for SSRI plasma level analyses.

Funding

The analysis is part of a larger study that was supported by the Austrian Science Fund (FWF) grant number KLI 516 to R.L., the Medical Imaging Cluster of the Medical University of Vienna, and by the grant „Interdisciplinary translational brain research cluster (ITHC) with highfield MR" from the Federal Ministry of Science, Research and Economy (BMFWF), Austria. M. K. and M. B. R. are recipients of a DOC-fellowship of the Austrian Academy of Sciences at the Department of Psychiatry and Psychotherapy, Medical University of Vienna.

Conflicts of Interest

There are no conflicts of interest to declare regarding the present study. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and Heel and has served as a consultant for Ono Pharmaceutical. He received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. D. Winkler received lecture fees/authorship honoraria within the last three years from Angelini, Lundbeck, MedMedia Verlag, and Medical Dialogue.

Ethics approval

This study is part of a larger project that has been approved by the ethics committee of the Medical University of Vienna (EK Nr.: 1739/2016) and performed in accordance with the Declaration of Helsinki (1964). The project is registered at clinicaltrials.gov with the identifier NCT02753738.

Availability of data and material

The full data can be made available upon reasonable request to the corresponding author.

References

- Adli M, Baethge C, Heinz A, Langlitz N, Bauer M (2005) Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. *European archives of psychiatry and clinical neuroscience* 255:387-400.
- Alboni S, van Dijk RM, Poggini S, Milior G, Perrotta M, Drenth T, Brunello N, Wolfer DP, Limatola C, Amrein I, Cirulli F, Maggi L, Branchi I (2017) Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. *Mol Psychiatry* 22:552-561.
- Andersson JLR, Sotiropoulos SN (2016) An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. *Neuroimage* 125:1063-1078.
- Andersson JLR, Graham MS, Zsoldos E, Sotiropoulos SN (2016) Incorporating outlier detection and replacement into a non-parametric framework for movement and distortion correction of diffusion MR images. *Neuroimage* 141:556-572.
- Andersson JLR, Jenkinson, M., and Smith, S. (2007a) Non-linear registration aka Spatial normalisation. In: *FMRIB Technical Report TR07JA2*. 22. Available at: www.fmrib.ox.ac.uk/analysis/techrep.
- Andersson JLR, Jenkinson, M., and Smith, S. M. (2007b) Non-linear optimisation. *FMRIB technical report TR07JA1*. In. Available at: www.fmrib.ox.ac.uk/analysis/techrep. Accessed Feb 22, 2013.
- Bainbridge WA, Isola P, Oliva A (2013) The intrinsic memorability of face photographs. *J Exp Psychol Gen* 142:1323-1334.
- Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive D (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 14:334-385.
- Bells S, Lefebvre J, Longoni G, Narayanan S, Arnold DL, Yeh EA, Mabbott DJ (2019) White matter plasticity and maturation in human cognition. *Glia* 67:2020-2037.
- Blumenfeld-Katzir T, Pasternak O, Dagan M, Assaf Y (2011) Diffusion MRI of structural brain plasticity induced by a learning and memory task. *PLoS one* 6:e20678.
- Branchi I, Giuliani A (2021) Shaping therapeutic trajectories in mental health: Instructive vs. permissive causality. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 43:1-9.
- Casarotto PC et al. (2021) Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. *Cell*.
- Chiarotti F, Viglione A, Giuliani A, Branchi I (2017) Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR*D study. *Transl Psychiatry* 7:e1066.
- Davis AD, Hassel S, Arnott SR, Harris J, Lam RW, Milev R, Rotzinger S, Zamyadi M, Frey BN, Minuzzi L, Strother SC, MacQueen GM, Kennedy SH, Hall GB (2019) White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. *Biol Psychiatry Cogn Neurosci Neuroimaging* 4:913-924.
- Debowska W, Wolak T, Nowicka A, Kozak A, Szwed M, Kossut M (2016) Functional and Structural Neuroplasticity Induced by Short-Term Tactile Training Based on Braille Reading. *Front Neurosci* 10:460.

- Delgado PL (2000) Depression: the case for a monoamine deficiency. *The Journal of clinical psychiatry* 61 Suppl 6:7-11.
- Dichter GS, Gibbs D, Smoski MJ (2015) A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. *Journal of affective disorders* 172:8-17.
- Draganski B, Gaser C, Busch V, Schuierer G, Bogdahn U, May A (2004) Neuroplasticity: changes in grey matter induced by training. *Nature* 427:311-312.
- Dvorak AV, Swift-LaPointe T, Vavasour IM, Lee LE, Abel S, Russell-Schulz B, Graf C, Wurl A, Liu H, Laule C, Li DKB, Traboulsee A, Tam R, Boyd LA, MacKay AL, Kolind SH (2021) An atlas for human brain myelin content throughout the adult life span. *Scientific reports* 11:269.
- Fan Q, Yan X, Wang J, Chen Y, Wang X, Li C, Tan L, You C, Zhang T, Zuo S, Xu D, Chen K, Finlayson-Burden JM, Xiao Z (2012) Abnormalities of white matter microstructure in unmedicated obsessive-compulsive disorder and changes after medication. *PloS one* 7:e35889.
- Ford MC, Alexandrova O, Cossell L, Stange-Marten A, Sinclair J, Kopp-Scheinpflug C, Pecka M, Attwell D, Grothe B (2015) Tuning of Ranvier node and internode properties in myelinated axons to adjust action potential timing. *Nat Commun* 6:8073.
- Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G (2019) Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. *The Lancet Psychiatry* 6:601-609.
- Gryglewski G et al. (2019) Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 29:711-719.
- Hartline DK, Colman DR (2007) Rapid conduction and the evolution of giant axons and myelinated fibers. *Curr Biol* 17:R29-35.
- Hiemke C et al. (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. *Pharmacopsychiatry* 44:195-235.
- Hofstetter S, Tavor I, Tzur Moryosef S, Assaf Y (2013) Short-term learning induces white matter plasticity in the fornix. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 33:12844-12850.
- Keller TA, Just MA (2009) Altering cortical connectivity: remediation-induced changes in the white matter of poor readers. *Neuron* 64:624-631.
- Knorr U, Madsen JM, Kessing LV (2019) The effect of selective serotonin reuptake inhibitors in healthy subjects revisited: A systematic review of the literature. *Exp Clin Psychopharmacol* 27:413-432.
- Kraus C, Castren E, Kasper S, Lanzenberger R (2017) Serotonin and neuroplasticity - Links between molecular, functional and structural pathophysiology in depression. *Neuroscience and biobehavioral reviews* 77:317-326.
- Kraus C, Ganger S, Losak J, Hahn A, Savli M, Kranz GS, Baldinger P, Windischberger C, Kasper S, Lanzenberger R (2014) Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake. *NeuroImage* 84:236-244.
- Kristensen TD, Mandl RCW, Jepsen JRM, Rostrup E, Glenthøj LB, Nordentoft M, Glenthøj BY, Ebdrup BH (2018) Non-pharmacological modulation of cerebral white matter organization: A systematic review of non-psychiatric and psychiatric studies. *Neuroscience and biobehavioral reviews* 88:84-97.

- Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheek A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [¹¹C]DASB positron emission tomography study. *The American journal of psychiatry* 161:826-835.
- Reed MB, Vanicek T, Seiger R, Klobl M, Spurny B, Handschuh P, Ritter V, Unterholzner J, Godbersen GM, Gryglewski G, Kraus C, Winkler D, Hahn A, Lanzenberger R (2021) Neuroplastic effects of a selective serotonin reuptake inhibitor in relearning and retrieval. *Neuroimage*:118039.
- Sagi Y, Tavor I, Hofstetter S, Tzur-Moryosef S, Blumenfeld-Katzir T, Assaf Y (2012) Learning in the fast lane: new insights into neuroplasticity. *Neuron* 73:1195-1203.
- Sampaio-Baptista C, Johansen-Berg H (2017) White Matter Plasticity in the Adult Brain. *Neuron* 96:1239-1251.
- Sampaio-Baptista C, Valles A, Khrapitchev AA, Akkermans G, Winkler AM, Foxley S, Sibson NR, Roberts M, Miller K, Diamond ME, Martens GJM, De Weerd P, Johansen-Berg H (2020) White matter structure and myelin-related gene expression alterations with experience in adult rats. *Prog Neurobiol* 187:101770.
- Scholz J, Klein MC, Behrens TE, Johansen-Berg H (2009) Training induces changes in white-matter architecture. *Nature neuroscience* 12:1370-1371.
- Seiger R, Gryglewski G, Klöbl M, Kautzky A, Godbersen GM, Rischka L, Vanicek T, Hienert M, Unterholzner J, Silberbauer LR, Michenthaler P, Handschuh P, Hahn A, Kasper S, Lanzenberger R (2021) The influence of acute SSRI administration on white matter microstructure in patients suffering from major depressive disorder and healthy controls. *The international journal of neuropsychopharmacology*.
- Shapiro BB (2018) Subtherapeutic doses of SSRI antidepressants demonstrate considerable serotonin transporter occupancy: implications for tapering SSRIs. *Psychopharmacology* 235:2779-2781.
- Shively CA, Silverstein-Metzler M, Justice J, Willard SL (2017) The impact of treatment with selective serotonin reuptake inhibitors on primate cardiovascular disease, behavior, and neuroanatomy. *Neuroscience and biobehavioral reviews* 74:433-443.
- Smith SM (2002) Fast robust automated brain extraction. *Human brain mapping* 17:143-155.
- Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, Watkins KE, Ciccarelli O, Cader MZ, Matthews PM, Behrens TE (2006) Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. *Neuroimage* 31:1487-1505.
- Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004) Advances in functional and structural MR image analysis and implementation as FSL. *Neuroimage* 23 Suppl 1:S208-219.
- Spies M, Knudsen GM, Lanzenberger R, Kasper S (2015) The serotonin transporter in psychiatric disorders: insights from PET imaging. *The lancet Psychiatry* 2:743-755.
- Spurny B, Vanicek T, Seiger R, Reed MB, Klobl M, Ritter V, Unterholzner J, Godbersen GM, Silberbauer LR, Pacher D, Klug S, Konadu ME, Gryglewski G, Trattig S, Bogner W, Lanzenberger R (2021) Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm. *Neuroimage* 232:117913.
- Takeuchi H, Sekiguchi A, Taki Y, Yokoyama S, Yomogida Y, Komuro N, Yamanouchi T, Suzuki S, Kawashima R (2010) Training of working memory impacts structural connectivity. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 30:3297-3303.
- Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, Team SDS

- (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *The American journal of psychiatry* 163:28-40.
- Wang S, Young KM (2014) White matter plasticity in adulthood. *Neuroscience* 276:148-160.
- Yoo SY, Jang JH, Shin YW, Kim DJ, Park HJ, Moon WJ, Chung EC, Lee JM, Kim IY, Kim SI, Kwon JS (2007) White matter abnormalities in drug-naïve patients with obsessive-compulsive disorder: a diffusion tensor study before and after citalopram treatment. *Acta Psychiatr Scand* 116:211-219.
- Yotsumoto Y, Chang LH, Ni R, Pierce R, Andersen GJ, Watanabe T, Sasaki Y (2014) White matter in the older brain is more plastic than in the younger brain. *Nat Commun* 5:5504.
- Zatorre RJ, Fields RD, Johansen-Berg H (2012) Plasticity in gray and white: neuroimaging changes in brain structure during learning. *Nature neuroscience* 15:528-536.
- Zeng LL, Liu L, Liu Y, Shen H, Li Y, Hu D (2012) Antidepressant treatment normalizes white matter volume in patients with major depression. *PloS one* 7:e44248.

FLOW DIAGRAM

Table 1: Flow-Diagram

Group	participants	# females	age (mean)	age (SD)
placebo_chinese	15	7	25.40	4.07
placebo_faces	23	16	25.78	5.49
verum_chinese	17	11	25.47	5.04
verum_faces	16	9	25.44	5.25

Table 2: Demographical information for subjects included in DTI analysis.